

Correspondence to:

Department of Neurology Faculty of Medicine and Dentistry Medical University of Warsaw Bielański Hospital Poland e-mail: piotr.chdzyski@gmail.com

Submitted: 24.08.2023 Accepted: 27.10.2023

Tolosa-Hunt syndrome: a review of diagnostic criteria based on a case series

Piotr R. Chądzyński D, Katarzyna Stopińska D, Izabela Domitrz

Department of Neurology, Faculty of Medicine and Dentistry, Medical University of Warsaw, Bielański Hospital, Poland

Abstract

Purpose: Tolosa-Hunt syndrome (THS) is a rare cause of painful ophtalmoplegia with different clinical manifestations. It is described as a unilateral periorbital headache with concomitant dysfunction of at least one out of the IIIrd, IVth and VIth cranial nerves due to the granulomatous inflammation of periorbital structures, but no underlying cause has been established.

Case description: We present six patients referred to the Neurology Department due to a unilateral headache with ipsilateral paresis of at least one cranial nerve responsible for eye movements. The THS diagnostic criteria of the International Headache Disorders Classification (ICHD-3) were applied and analysed. Few patients had atypical clinical manifestations according to these criteria.

Comment: Diagnosing THS may prove very challenging. There is a lack of specific markers for the disorder, whereas diagnostic criteria leave a wide area for misdiagnosis. The diagnostic approach should be focused on the exclusion of other pathologies because typical steroid therapy may prove fatal in otherwise benign cases.

Key words: pain, case report, headache, Tolosa-Hunt syndrome, ophtalmoplegia.

PURPOSE

Tolosa-Hunt syndrome (THS) is a rare cause of painful ophtalmoplegia with an estimated annual incidence of 1 case per million in the general population [1]. The first case of a patient diagnosed with THS was described by Dr E. Tolosa in 1954 and since then numerous cases have been reported [2-5]. In 1988 the International Headache Society established the first diagnostic criteria for THS, which has evolved over the years [4]. According to the current diagnostic criteria included in the third edition of the International Classification of Headache Disorders (ICHD-3), THS is defined as a unilateral headache with ipsilateral paresis of at least one cranial nerve responsible for eye movement due to idiopathic granulomatous inflammation of periorbital areas [6]. Despite the many studies on THS, its underlying cause is still unknown [7]. The full diagnostic criteria in accordance with ICHD-3 are presented in Table 1. The authors would like to present a case series of six patients suffering from painful ophtalmoplegia, who were hospitalized in the same hospital in Warsaw in Poland and discuss the possible challenges in the context of THS diagnosis.

CASE DESCRIPTION

The following cases involve six patients hospitalized in the Neurology Department of Bielanski Hospital in Warsaw due to painful ophtalmoplegia symptoms. The retrospectively analysed patients had been hospitalized between 2018 and 2022. Patient number 6 gave consent for visual content relating to their case to be published. The clinical features of our patients are presented in Table 2, whereas in Table 3 the results of laboratory and neuroimaging tests are shown.

Case 1

During a period of three years, between the ages of 61 and 64, this woman suffered from four episodes of left-sided headache with ipsilateral eye movement impairment. The episodes were separated by headache-free periods that lasted, respectively, 22, 10 and 4 months. All four episodes had a similar manifestation of constant, severe pain localized on the left side of the forehead and in the left orbital region, behind the eyeball. The pain increased with horizontal eye movements and had a short response to simple analgesics. An inability to achieve

Table 1. Tolosa-Hunt syndrome diagnosis criteria according to the ICHD-3

- A. Unilateral orbital or periorbital headache fulfilling criterion C
- B. Both of the following:
 - 1. Granulomatous inflammation of the cavernous sinus, superior orbital fissure or orbit, demonstrated by MRI or biopsy
 - 2. Paresis of one or more of the Illrd, IVth and/or VIth ipsilateral cranial nerves
- C. Evidence of causation demonstrated by both of the following:
 - 1. Headache is ipsilateral to the granulomatous inflammation
 - 2. Headache has preceded paresis of the IIIrd, IVth and/or VIth nerves by ≤ 2 weeks, or developed with it
- D. Not better accounted for by another ICHD-3 diagnosis.

Table 2. Clinical features and patients' symptoms

Patient number	Age	Sex	Year of onset	Duration of pain prior to hospitalization (days)	Duration of eye movement disorders (days)	The nature of the pain	Pain localization	Cranial nerves involved	Other diseases
1	61	F	2019	Episode II: 2 Episode II: 3 Episode III: 3 Episode IV: 3	Each episode around 5 days	Each episode with very strong intensity	Each episode the left side of the forehead and in the left orbital region, behind the eyeball.	Each episode: right oculomotor	Hypertension, coronary heart disease
2	56	М	2021	30	30	Moderate	Left eyeball/ left side of the head	Left abducens	Hypertension, psoriasis
3	82	F	2020	14	5	Moderate, compressive	Left eyeball; temporal- parietal area	Left oculomotor	Paroxysmal supraventricular tachycardia, hypertension, state after iodine nodular goitre therapy
4	65	F	2018	Episode II: 7 Episode II: 4	1	Very strong	Episode I: right eyeball; right-sided headache Episode II: left- sided	Episode I: right oculomotor, first branch of the right trigeminal nerve Episode II: left oculomotor	Hypertension, type 2 diabetes mellitus, head trauma
5	40	F	2020	20	2	Increasing in pressure	Left eye socket	Left oculomotor	Hypertension, type 1 diabetes mellitus, tachycardia, anxiety disorders
6	56	М	2022	60	5	Prickly pain of middle part of the face	Right-sided headache	III rd , IV th and VI th on the right side	Hypertension, obesity, dyslipidemia

F – female, M – male

complete abduction and adduction in the affected eye was observed. Additionally, during the first episode soft tissue swelling and slight exophthalmos were noted, and during the third episode the patient reported transient diplopia. There were no additional abnormalities during the neurological examination. In the medical history, the patient reported hypertension, coronary heart disease, lipid metabolism disorder and ischemic brain stroke. A blood test showed only a slightly elevated

level of C-reactive protein (CRP), the rest of the blood tests were normal. Computed tomography (CT) with angiography and magnetic resonance imaging (MRI) of the brain (1.5 T, 3 mm thickness), performed during every single relapse, showed normal findings. The patient was treated with intravenous injections of methylprednisolone in the dose of 1,000 mg daily for 5 days, followed by oral steroid therapy of 40-60 mg of prednisolone in gradually decreasing doses (specified in Table 4).

Table 3. Neuroimaging and laboratory tests results

Patient number	Neuroimaging	CRP (mg/l; 0-5)	WBC (× 10°/μl)	Neutrophils (× 10°/µl)	Lymphocytes (× 10°/μl)	CSF cell counts (cells/µl; 0-5)	CSF protein (mg/dl; 15-45)	CSF opening pressure
1	Each episode: MRI and angio-MRI – without significant deviations	I: 6.97 II: 28.79 III: 10.19 IV: 9.11	I: 6.61 II: 5.59 III: 6.43 IV: 5.98	I: 4.30 II: 3.52 III: 3.19 IV: 3.22	I: 1.60 II: 1.43 III: 2.19 IV: 2.10	LP was not performed	-	-
2	Orbital MRI – excess tissue in the left cavernous sinus; head and neck angio-CT – ICAL blood blister-like aneurysms (BBA) in C1	3.21	11.62	8.45	2.20	LP was not performed	-	_
3	MRI, angio-MRI – inflammatory changes in the left sphenoid sinus; in CT without bone destruction	< 1.00	6.68	4.31	1.45	2	40.25	Normal
4	Both episodes: MRI and angio-MRI – without significant deviations	I: 0.82 II: < 1.00; 138; 317; 333	l: 12.01 ll: 8.74; 20.69; 20.90; 43.54	l: 6.55 ll: 4.92; 18.81; 17.62; 34.54	I: 4.36 II: 2.97; 1.08; 1.89; 6.60	Episode I: 1 cell Episode II: not performed	22.43	Normal
5	MRI and angio-MRI – without significant deviations	< 1.00	10.42	8.14	1.58	1	24.8	Normal
6	MRI – post-contrast enhancement and thickening up to 6 mm within the cavernous sinus towards the upper orbital fissure and the top of the orbit	9.33	7.43	4.48	2.31	LP was not performed	-	-

CRP - C-reactive protein, WBC - white blood cells, CSF - cerebrospinal fluid, LP - lumbar puncture

Prompt recovery was observed with complete relief of pain and symptoms.

Case 2

A 56-years-old man was admitted to the hospital around 4 weeks after the first symptoms, consisting of double vision accompanied by severe periorbital pain on the left side. In later stages pain covered the entire half of the head on the same side. The neurological examination showed paresis of the left abducens nerve and slight weakness of the right upper limb (residual weakness after a cervical spine operation). All blood tests were normal. MRI of the brain and the eye sockets (1.5 T, 3 mm thickness) showed slight excess tissue in the cavernous sinus and blood blister-like aneurysms (BBA) on the internal carotid artery. The medical history of the patient showed hypertension and psoriasis. The patient was treated with intravenous methylprednisolone in the dose of 1,000 mg daily for 5 days. Oral steroid therapy was not implemented. The headache disappeared after 24 hours following the beginning of the treatment, followed by a full recovery over the next few days.

Case 3

An 82-years-old woman was admitted to the hospital due to a headache lasting for two weeks. The pain was localized in the left temporal-parietal area and behind the left eyeball. During the second week of the pain, double vision and ptosis of the left eyelid occurred. The pain had compressive characteristics and moderate intensity. The neurological examination showed paresis of the left oculomotor nerve. Blood tests did not show any abnormalities. MRI of the brain with angiography showed mucosal changes in the sphenoid sinus on the left side. The patient was treated with intravenous methylprednisolone of 1,000 mg daily dose for 5 days, followed by oral steroid therapy of 30 mg (prednisolone, over a total of 22 days). A rapid clinical improvement was observed after the treatment.

Case 4

A 65-year-old woman was examined due to severe pain in the right orbit lasting for one week. The day before her admission to the hospital, double vision occurred. Neurological examination revealed dysfunction of the right oculomotor nerve and the first branch of the trigeminal cranial nerve on the same side. The medical history showed obesity and diabetes mellitus (DM) type 2 (with normal glucose levels). Extensive blood and cerebrospinal fluid (CSF) examinations showed normal results. MRI of the brain was normal. The introduction of pulse corticosteroid therapy (methylprednisolone, 0.5 g for 5 days – reduced doses due to DM) followed by oral ste-

Table 4. Applied treatment with observed effects

Patient number	First linetreatment (i.v.)	Follow-up treatment (oral)	Effects of treatment	Adverseeffects
1	All episodes: 1000 mg of i.v. methylprednisolone per day (5 days courses)	Episode I: 60 mg of prednisone per day, reduction by 5 mg each day (total of 12 days) Episode II: 60 mg of prednisone per day, reduction by 5 mg each day (total of 12 days) Episode III: 40 mg of prednisone per day, reduction by 5 mg each 3 days (total of 24 days) Episode IV: 40 mg of prednisone per day, reduction by 5 mg each 3 days (total of 24 days)	All episodes: pain relief (first 24h); remission of motor symptoms	All episodes: none
2	1000 mg of <i>i.v.</i> methylprednisolone per day (5 days course)	None	Pain relief (first 24 h); full remission of the left abducens nerve paresis	None
3	1000 mg of <i>i.v.</i> methylprednisolone per day (5 days course)	30 mg of prednisone per day, reduction by 5 mg each 3 days (total of 22 days)	Pain relief on day (within 48 h); improvement of paresis	None
4	Both episodes: 1000 mg of <i>i.v.</i> methylprednisolone per day (5 days course)	Episode I: 60 mg of oral prednisone per day (total of 28 days) Episode II: none	Episode I: pain relief (first 24 h); full remission of paresis Episode II: pain relief (first 48 h); paresis improvement	Episode I: none Episode II: abscess of the right subclavicular region, sepsis of <i>S. aureus</i> MSSA aetiology, death
5	1000 mg of i.v. methylprednisolone per day (5 days course)	20 mg of oral prednisone per day for 7 days, followed by reduced dose by 5 mg and further reduction of doses by 5 mg each 3 days (total of 24 days)	Pain relief (first 24 h); full remission of paresis	None
6	1000 mg of <i>i.v.</i> methylprednisolone per day (7 days course)	60 mg of prednisone per day, reduction by 5 mg each 3 days (total of 36 days)	Pain relief; improvement of paresis	None

roid therapy (60 mg of prednisolone per day in gradually decreasing doses) reduced headache and decreased neurological deficits. Nearly one year later, the symptoms recurred on the other side of the patient's head; she suffered from a severe periorbital headache with double and blurred vision. The neurological examination showed the pupil in the left eye to be dilated, with poor light response, partial ptosis and paresis of the left oculomotor nerve. There were no significant changes in the blood tests on admission to the hospital. The MRI of the brain was repeated and no abnormalities were found. Treatment with intravenous steroid therapy was started (5 days of 1,000 mg of methylprednisolone per day), with the rapid improvement of symptoms (the headache disappeared during the first 24 hours). On the fifth day of treatment, the patient reported pain in the right subclavicular region. The affected subclavicular area appeared reddened and warmer. Ultrasonography was performed that showed a possible abscess forming in the soft tissues of the painful area. Blood tests showed increased markers of inflammation (CRP, leukocytes). Antibiotics were administered empirically (clindamycine). Blood culture tests were performed which showed positive results and identified Staphylo-

coccus aureus MSSA type, therefore antibiotic therapy was modified (with the addition of cefotaxime). On the tenth day of the hospitalization, a respiratory and circulatory failure occurred due to sepsis, which led to the death of the patient.

Case 5

A 40-year-old woman was admitted to the hospital due to a headache in the left orbital area with visual disturbances. The symptoms occurred 2-3 weeks before the patient was referred to the hospital. Two days before the hospitalization, double vision occurred. The patient was treated with antibiotics by her general practitioner (GP), who suspected sinusitis. The neurological examination showed left oculomotor paresis and slight paresis of the left abducens nerve. DM type 1 was reported in the patient's medical history. During the hospitalization, hypertension was diagnosed. Blood tests were normal. MRI of the brain and the eye sockets were normal. The patient was treated with intravenous methylprednisolone in the dose of 1,000 mg daily for 5 days, followed by oral steroid therapy over 24 days (40 mg of prednisolone in gradually decreasing doses). Rapid improvement was observed after the therapy.

Case 6

A 56-year-old man was admitted to the hospital due to double vision, a problem with the mobility of the right eyeball, and a right-sided headache. The first symptoms were not so obvious due to a prickly headache in the middle of the face, with swelling on its right side. Around 7-8 weeks later typical symptoms appeared, consisting of severe right-sided periorbital headache and ipsilateral eye movement disorder. In the meantime, the patient was treated with antibiotics by a dentist due to suspected peroidontitis. The neurological assessment showed ophthalmoplegia of the right eyeball, ptosis, and exophthalmos. The MRI findings showed asymmetrical reinforcement and thickening up to 6 mm within the cavernous sinus on the right side, laterally directed towards the superior orbital fissure and the top of the orbit. The MRI findings are shown in Figure I and Figure II. Treatment with intravenous steroid was started (1,000 mg of methylprednisolone daily for 7 days), with an improvement of the symptoms, followed by oral steroid of 60 mg of prednisolone in

gradually decreasing doses over 36 days. The rapid clinical improvement was observed as shown in Figures III to VI. We also include a video showing the patient's eye motor functions on the 7^{th} day of the treatment.

PATIENT PERSPECTIVE

All the patients gave informed consent to diagnostic procedures and treatment. There were no major complaints, and adverse effects due to the treatment in each case are presented in Table 4. The only exception was the second episode of patient number 4, with the occurrence of severe adverse effects as described previously.

DISCUSSION

Although the ICHD-3 diagnostic criteria for THS demand the confirmation of the inflammatory process via neuroimaging or biopsy, only two of our patients met this criterion [6]. Pathological effects may be absent in






Figure I. Patient number 6. Axial MRI T2 sequences showing asymmetrical thickening up to 6 mm within the right cavernous sinus, laterally directed towards the superior orbital fissure and the top of the orbit





Figure II. Patient number 6. Axial MRI T1 sequences with contrast showing asymmetrical reinforcement within the right cavernous sinus




Figure III. Patient number 6 on the second day of the hospitalization in the Neurology Department before the treatment. Ptosis and ophthalmoplegia were observed on the right side



Figure IV. Patient number 6 after one day of intravenous methylprednisolone treatment



Figure V. Patient number 6 after five days of intravenous methylprednisolone treatment

the neuroimaging tests due to technical limitations (e.g. resolution) or a too-early performance of MRI [8]. We chose not to perform a biopsy due to the high risk of exceeding the potential benefits for the patients. Likewise, numerous cases can be found in the literature of typical clinical manifestations of THS without confirmation of inflammatory process [8-10]. Approximately up to 50% of typical THS cases are reported without inflammatory findings in the neuroimaging within the typical areas (cavernous sinus, superior orbital fissure or orbit) [9, 10]. Such cases are referred to as "benign THS", as opposed to the inflammatory cases of the condition [8]. Other possible causes of painful ophtalmoplegia without abnormal neuroimaging findings include disorders such as DM polineuropathy or recurrent painful ophtalmoplegic neuropathy (previously classified as ophtalmoplegic migraine) [10]. Two of our patients had a previous history of DM, but we excluded this etiology due to normal glucose levels (at the fasting and 4-point profile). In the case of patient number 1, with four recurrent episodes, we did differentiate between THS and recurrent painful ophtalmoplegic neuropathy. We concluded that THS was more probable due to a good response to the steroid therapy.

High responsiveness to the steroid treatment was included in the previous diagnostic criteria of THS in both the first and second editions of the ICHD [11]. In the current third edition, steroid responsiveness was excluded from the THS criteria, but it is still mentioned as an additional factor supporting the diagnosis [6]. Most clinical reports support the high effectiveness of steroids in the treatment of THS [9, 12]. All our patients were treated with steroid therapy, after which their condition improved rapidly, especially when it came to the pain component. There were no significant adverse effects reported, except for patient number 4 (inflammation resulting in death). Comparably, Rodriguez et al. reported the case of a 57-year-old patient primarily misdiagnosed with THS with pathological findings within the cavernous sinus [13]. In this case a 3-day course of methylprednisolone was ineffective, followed by a worsening of the patient's condition and resulting in death [13]. Post-mortem examination revealed actinomyces cavernous sinus infection [13]. This particular case is quite similar to the second episode of our patient number 4. The anti-inflammatory effect of steroids probably exacerbated the bacterial infection, resulting in the serious adverse effects of the therapy. Every day careful observation of the patient is a very important part of steroid treatment because new symptoms of infection can occur each day.

Unfortunately, many other disorders mimicking THS may also improve during the initial stages of steroid therapy (e.g. neoplasms) [2]. Mendonca *et al.* reported a case in which an initial diagnosis of THS was later revealed to be Eales disease during the follow-up [14]. Similarly, Brandy-Garcia *et al.* reported a case of a 55-year-old woman presenting THS symptoms, who was diagnosed



Figure VI. Patient number 6 one month from the 1st day of treatment

with sarcoidosis after additional testing [15]. Both patients improved after the steroid treatment, which could lead to misdiagnosis. In each case of suspected THS, the treatment should be started very carefully and only after the exclusion of other pathologies. This is consistent with the last section of the THS diagnostic criteria, stating that the symptoms cannot be better accounted for by any other ICHD-3 criteria [6].

The initial findings of the laboratory tests performed on our patients did not show any significant abnormalities. Other studies confirm that blood test results stay within the normal range during THS episodes, while elevated inflammatory markers should be an alarming signal of other etiologies [7, 13]. A lumbar puncture was performed in three of our patients. Each time the opening pressure was within the normal range and no abnormalities were found in the basic analysis. Yang et al. performed a detailed cerebrospinal fluid analysis of 55 THS cases [16]. The study showed elevated protein levels in about 27% of the cases and oligoclonal antibodies were found in 29% of the patients. Intrathecal antibodies synthesis was statistically more frequent when THS symptoms lasted for less than 30 days, suggesting an active inflammatory process. The presence of oligoclonal bands can prove useful in future diagnostic approaches.

The period between the first eye movement disorders and the first headache symptoms in our patients varied between 0 to 55 days. According to the ICHD-3, this period should not be longer than 14 days in THS patients, as a confirmation of a temporal relation between the symptoms [6]. Two of our patients exceeded the time limit by 4 and 41 days respectively. However, we applied steroid therapy for both of them with good results. Not many researchers elaborate on this aspect, but there are reported cases of patients exceeding the period of 14 days and still being treated successfully with steroids [4].

Beside the involvement of the IIIrd, IVth and VIth cranial nerves in THS, there is always a possibility that additional cranial nerves are involved. The involvement of each cranial nerve varies between studies [7, 9]. There are reported cases involving the IIth, Vth, VIIth and VIIIth cranial nerves [6, 12, 17, 18]. In the case of the first episode of our patient number 4, the neurological examination showed dysfunction of the first branch of the trigeminal nerve ipsilateral to other symptoms. Furthermore, there are seldom bilateral THS manifestations (up to 5%) [19].

Mullen *et al.* concluded that THS diagnostic criteria are suboptimal, whereas Dutta *et al.* implied that THS should be renamed for a wider spectrum of clinical situations [2, 11]. Current diagnostic criteria leave a wide area for misdiagnosis, especially at the early stages of the disorder.

CONCLUSIONS

In the end, only one of the 6 patients analysed (patient number 2) met the full criteria for THS according to the ICHD-3. Nevertheless, all of them were treated successfully with the exact same steroid therapy. In our opinion, the key factor in the diagnostic process is the exclusion of other pathologies, rather than confirming idiopathic inflammation within periorbital structures. One of the most important factors regarding steroid treatment is its anti-inflammatory effect, which can exacerbate infections. We suggest a thorough and full examination of the patient before implementing steroid treatment and a careful follow-up for a potential misdiagnosis. Currently, there are neither specific biochemical (e.g., inflammatory) nor neuroimaging markers for THS diagnostics. Therefore further studies are needed, as well as a review of diagnostic criteria.

Conflict of interest

Absent.

Financial support

Absent.

References

- Iaconetta G, Stella L, Esposito M, Cappabianca P. Tolosa-Hunt syndrome extending in the cerebellopontine angle. Cephalalgia 2005; 25: 746-750.
- 2. Mullen E, Rutland JW, Green MW, Bederson J, Shrivastava R. Reappraising the Tolosa-Hunt syndrome diagnostic criteria: a case series. Headache 2020; 60: 259-264.
- 3. Hao R, He Y, Zhang H, Zhang W, Li X, Ke Y. The evaluation of ICHD-3 beta diagnostic criteria for Tolosa-Hunt syndrome: a study of 22 cases of Tolosa-Hunt syndrome. Neurol Sci 2015; 36: 899-905.
- 4. Zhang X, Zhou Z, Steiner TJ, Zhang W, Liu R, Dong Z, et al. Validation of ICHD-3 beta diagnostic criteria for 13.7 Tolosa-Hunt syndrome: analysis of 77 cases of painful ophthalmoplegia. Cephalalgia 2014; 34: 624-632.
- 5. Tolosa E. Periarteritic lesions of the carotid siphon with the clinical features of a carotid infraclinoidal aneurysm. J Neurol Neurosurg Psychiatry 1954; 17: 300-302.
- Vincent M, Wang S. The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38: 1-211.
- 7. Kim H, Oh SY. The clinical features and outcomes of Tolosa-Hunt syndrome. BMC Ophthalmol 2021; 21: 237. DOI: 10.1186/s12886-021-02007-0.
- 8. Hung CH, Chang KH, Wu YM, Chen YL, Lyu RK, Chang HS, et al. A comparison of benign and inflammatory manifestations of Tolosa-Hunt syndrome. Cephalalgia 2013; 33: 842-852.
- 9. Podgorac A, Zidverc-Trajković J, Jovanović Z, Ristić A, Radojicić A, Pavlović A, et al. Tolosa-Hunt syndrome: is it really necessary to show granuloma? The report on eight cases. Vojnosanit Pregl 2017; 74: 287-293.
- 10. Hung CH, Chang KH, Chu CC, Liao MF, Chang HS, Lyu RK, et al. Painful ophthalmoplegia with normal cranial imaging. BMC Neurol 2014; 14: 7. DOI: 10.1186/1471-2377-14-7.
- Dutta P, Anand K. Tolosa-Hunt syndrome: a review of diagnostic criteria and unresolved issues. J Curr Ophthalmol 2021; 33: 104. DOI: 10.4103/joco.joco_134_20.
- 12. Zhang X, Zhang W, Liu R, Dong Z, Yu S. Factors that influence Tolosa-Hunt syndrome and the short-term response to steroid pulse treatment. J Neurol Sci 2014; 341: 13-16.
- 13. Rodríguez SS, Gómez-Muga JJ, Onandi RR, Gallarreta ZD, García-Moncó JC. A 57-year-old man with painful ophthalmoplegia and cavernous sinus involvement: Why this is not Tolosa-Hunt syndrome. Eur J Neurol 2022; 29: 3127-3129.

Tolosa-Hunt syndrome: a review of diagnostic criteria based on a case series

- 14. Mendonça MD, Guedes M, Matias G, Costa J, Viana-Baptista M. Steroid-responsive painful ophthalmoplegia: Tolosa-Hunt syndrome, Eales disease, or both? Cephalalgia 2017; 37: 191-194.
- 15. Brandy-García A, Suárez-Cuervo C, Caminal-Montero L. Tolosa-Hunt syndrome as an initial presentation of sarcoidosis. Reumatol Clin (Engl Ed) 2021; 17: 178-179.
- 16. Yang Q, Lai C, Meng C, Chang Q, Wang J. Clinical and cerebrospinal fluid characteristics in 55 cases of Tolosa-Hunt syndrome: a retrospective analytical study. Eur Neurol 2022; 85: 265-272.
- 17. Rekik M, Kammoun S, Moalla KS, Abdelhedi MM. Tolosa-Hunt syndrome: a rare entity. J Neurol Sci 2021; 429: 118483. DOI: 10.1016/j.jns.2021.118483.
- 18. Thu PW, Chen YM, Liu WM. Recurrent Tolosa-Hunt syndrome. Tzu Chi Med J 2020; 33: 314-316.
- 19. Cowie M, Duncan R, Alamri Y. From left to right: an unusual presentation of Tolosa-Hunt syndrome with bilateral eye involvement. N Z Med J 2021; 134: 175-178.